Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 871

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Ravi K Goyal, MS, Saurabh P Nagar, MS, Shaum M Kabadi, PhD MPH, Keith L Davis, MA, Hannah Le, PharmD, MPH, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 796.

https://doi.org/10.1182/blood-2019-122842

Published: 2019

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh

Blood (2019) 134 (Supplement_1): 4720.

https://doi.org/10.1182/blood-2019-128876

Published: 2019

Journal Articles

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2019) 134 (Supplement_1): 1739.

https://doi.org/10.1182/blood-2019-121772

Published: 2019

Journal Articles

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Blood (2019) 134 (Supplement_1): 1740.

https://doi.org/10.1182/blood-2019-122037

Published: 2019

Journal Articles

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Seth Kuranz, MPH, Jennifer Stacey, BS, Sierra Luciano, BS

Blood (2019) 134 (Supplement_1): 1749.

https://doi.org/10.1182/blood-2019-130848

Published: 2019

Journal Articles

Mutational Landscape of Grey Zone Lymphoma

Blood (2019) 134 (Supplement_1): 21.

https://doi.org/10.1182/blood-2019-127375

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Blood (2019) 134 (Supplement_1): 36.

https://doi.org/10.1182/blood-2019-125825

Published: 2019

Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2192.

https://doi.org/10.1182/blood-2019-123980

Published: 2019

Journal Articles

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Martin W. Schoen, MDMPH, Peter Georgantopoulos, MS, Nagasai S Yalavarthi, BS, Charles L. Bennett, MD PhD

Blood (2019) 134 (Supplement_1): 2135.

https://doi.org/10.1182/blood-2019-121770

Published: 2019

Journal Articles

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Thura Win Htut, MBBS, MRCP, Nicholas D'Cunha, MD, Sariya Wongsaengsak, MD, Donald P. Quick, MD, Khaing Khaing Htwe, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Akshar Dash, Fred Hardwicke, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 2200.

https://doi.org/10.1182/blood-2019-123261

Published: 2019

NARROW

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Mutational Landscape of Grey Zone Lymphoma

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only